Bespak PLC
24 April 2006


For immediate release                                              24 April 2006

                                   Bespak plc
                                ('the Company')


    Bespak and Bang & Olufsen Medicom Collaborate on Next Generation Inhaler
   New Inhaler features integrated dose counter and easy-to-operate mechanism


Bespak plc (LSE: BPK), a leader in specialty medical devices, and Bang & Olufsen
Medicom, an innovative drug delivery device solutions provider, are pleased to
jointly announce today that they have entered into an exclusive partnership to
co-develop and co-market a single increment dose-counting inhaler.  This will be
the first integrated dose-counting device to feature an assisted firing
mechanism which will aid patient use.

The partnership has been formed to develop a next generation "press and breathe"
inhaler which will be aimed at the expanding Asthma and COPD (Chronic
Obstructive Pulmonary Disease) market.  Bang & Olufsen's intellectual property
in the area of design and development will be enhanced by Bespak's in-depth
understanding of valve technologies and precision of dose delivery, both of
which are essential to the development of any reliable dose-counting mechanism.
The two companies will share responsibility for the development, manufacture and
co-promotion of the device.

The functionality of the device has been thoroughly validated and is ready for
incorporation into a metered dose inhaler programme immediately.  Bespak and
Bang & Olufsen Medicom are currently seeking alliances with pharmaceutical
companies interested in providing new inhaler solutions for patients.



Mark Throdahl, Chief Executive Officer of Bespak, said: "Bang & Olufsen Medicom
has a strong design based heritage and an insight into patient compliance. In
particular, we think their dose-counting mechanism will bring a lot of value to
the collaboration. Together, our joint forces enable us to bring the device to
the market in high volumes within strict quality and design guidelines."

Welcoming the news from Bang & Olufsen Medicom, Chief Executive Officer Henrik
Kagenow, said: "We are excited it will be the first patient compliance device on
the market with a dose counter that meets FDA requirements. We are delighted to
work with Bespak, who are recognised leaders in the field of inhalation valves
and bring a wealth of inhaler manufacturing expertise to the partnership."

                                      ENDS

For further information please call:

Bespak plc
Mark Throdahl - Chief Executive                          +44 (0) 20 1908 552 600
Martin Hopcroft - Group Finance Director

Buchanan Communications                                     +44 (0) 20 7466 5000
Tim Thompson / Mark Court / Mary-Jane Johnson




Notes for Editors:

About Bespak plc

Bespak, a leader in specialty medical devices, develops delivery systems for the
pharmaceutical industry and disposable airway management products for critical
care settings.  Bespak's product range includes metered dose and dry powder
inhalers, actuators, inflation valves, disposable face masks, breathing circuits
and laryngeal tubes.  The group, which has facilities in King's Lynn and Milton
Keynes in the UK and Indianapolis and Kent, Ohio, in the US, is quoted on the
Official List of the London Stock Exchange (LSE: BPK).  For more information,
please visit www.bespak.com.

About Bang & Olufsen Medicom

Bang & Olufsen Medicom is a leading expert in the design, development and supply
of innovative drug delivery device solutions and sensor based technologies.  The
current product range includes; inhalers, tablet reminders and injection pens
with a focus on patient compliance. Bang & Olufsen Medicom offers concept
development, engineering and manufacturing services to clients with options to
licence its intellectual property. For more information you can visit: http://
www.medicom.bang-olufsen.com

Asthma and COPD

The pMDI (pressurised Metered Dose Inhalers) market is believed to have a
worldwide volume of 400 million units.  Asthma is a chronic inflammation of the
airways that is marked by continuous laboured breathing accompanied by wheezing,
breathlessness, a sense of constriction in the chest and coughing or gasping
attacks.

Chronic obstructive pulmonary disease (COPD) is often, though not always, caused
by smoking. COPD is a pulmonary disease that is characterized by chronic,
typically irreversible airway obstruction resulting in a slowed rate of
exhalation. The airflow limitation is associated with an abnormal inflammatory
response of the lungs to noxious particles or gases.

Patient compliance rates in Asthma and COPD are estimated to be in the region of
50%, a significant contributor to patient non compliance is said to be both
forgetfulness and the lack of visibility on dose tracking.

Image bank

To download images of the Inhaler (Assist Actuated InhalerTM) please visit the
Bang & Olufsen Medicom center: 
http://mediacenter.bang-olufsen.dk/MediaCenter/mc.nsf simply register the first 
time you visit.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRASEIFELSMSEFL